Radiolabelled agents for PET imaging of tumor hypoxia

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3282-3289

  Kurihara, H ^a   Honda, N ^a   Kono, Y ^a   Arai, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

18F FAZA; 18F FETNIM; 18F FMISO; Cu ATSM; Hypoxia; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; DIACETYL BIS(METHYLTHIOSEMICARBAZONE) CU; FLUORINE 18; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; NITROIMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

DRUG STRUCTURE; HUMAN; HYPOXIA; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR CELL; TUMOR HYPOXIA;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; ISOTOPE LABELING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84863761145     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215964     Document Type: Review

References (66)

1. Thomlinson, R. H.; Gray, L. H., The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9 (4), 539-49.
2. Padhani, A. R., Where are we with imaging oxygenation in human tumours? Cancer Imaging 2005, 5, 128-30.
3. Moulder, J. E.; Rockwell, S., Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987, 5 (4), 313-41.
4. Durand, R. E., Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 1991, 20 (2), 253-8.
5. Giaccia, A. J., Hypoxic Stress Proteins: Survival of the Fittest. Semin Radiat Oncol 1996, 6 (1), 46-58.
6. Riva, C.; Chauvin, C.; Pison, C.; Leverve, X., Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res 1998, 18 (6B), 4729-36.
7. Haroon, Z. A.; Raleigh, J. A.; Greenberg, C. S.; Dewhirst, M. W., Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann Surg 2000, 231 (1), 137-47.
8. Koong, A. C.; Denko, N. C.; Hudson, K. M.; Schindler, C.; Swiersz, L.; Koch, C.; Evans, S.; Ibrahim, H.; Le, Q. T.; Terris, D. J.; Giaccia, A. J., Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000, 60 (4), 883-7.
9. Czekay, R. P.; Aertgeerts, K.; Curriden, S. A.; Loskutoff, D. J., Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003, 160 (5), 781-91.
10. Semenza, G. L., Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007, 2007 (407), cm8.
11. Belozerov, V. E.; Van Meir, E. G., Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005, 16 (9), 901-9.
12. Vaupel, P., The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9 Suppl 5, 10-7.
13. Krohn, K. A.; Link, J. M.; Mason, R. P., Molecular imaging of hypoxia. J Nucl Med 2008, 49 Suppl 2, 129S-48S.
14. Procissi, D.; Claus, F.; Burgman, P.; Koziorowski, J.; Chapman, J. D.; Thakur, S. B.; Matei, C.; Ling, C. C.; Koutcher, J. A., In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res 2007, 13 (12), 3738-47.
15. Mees, G.; Dierckx, R.; Vangestel, C.; Van de Wiele, C., Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009, 36 (10), 1674-86.
16. Mason, R. P.; Zhao, D.; Pacheco-Torres, J.; Cui, W.; Kodibagkar, V. D.; Gulaka, P. K.; Hao, G.; Thorpe, P.; Hahn, E. W.; Peschke, P., Multimodality imaging of hypoxia in preclinical settings. Q J Nucl Med Mol Imaging 54 (3), 259-80.
17. Jerabek, P. A.; Patrick, T. B.; Kilbourn, M. R.; Dischino, D. D.; Welch, M. J., Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum A 1986, 37 (7), 599-605.
18. Yang, D. J.; Wallace, S.; Cherif, A.; Li, C.; Gretzer, M. B.; Kim, E. E.; Podoloff, D. A., Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995, 194 (3), 795-800.
19. Grierson, J. R.; Link, J. M.; Mathis, C. A.; Rasey, J. S.; Krohn, K. A., A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989, 30 (3), 343-50.
20. Lim, J. L.; Berridge, M. S., An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot 1993, 44 (8), 1085-91.
21. Tochon-Danguy, H. J.; Sachinidis, J. I.; Chan, F.; Chan, J. G.; Hall, C.; Cher, L.; Stylli, S.; Hill, J.; Kaye, A.; Scott, A. M., Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002, 29 (2), 191-7.
22. Kubota, K.; Tada, M.; Yamada, S.; Hori, K.; Saito, S.; Iwata, R.; Sato, K.; Fukuda, H.; Ido, T., Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999, 26 (7), 750-7.
23. Lawrentschuk, N.; Poon, A. M.; Foo, S. S.; Putra, L. G.; Murone, C.; Davis, I. D.; Bolton, D. M.; Scott, A. M., Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 2005, 96 (4), 540-6.
24. Zimny, M.; Gagel, B.; DiMartino, E.; Hamacher, K.; Coenen, H. H.; Westhofen, M.; Eble, M.; Buell, U.; Reinartz, P., FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006, 33 (12), 1426-31.
25. Gagel, B.; Piroth, M.; Pinkawa, M.; Reinartz, P.; Zimny, M.; Kaiser, H. J.; Stanzel, S.; Asadpour, B.; Demirel, C.; Hamacher, K.; Coenen, H. H.; Scholbach, T.; Maneschi, P.; DiMartino, E.; Eble, M. J., pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007, 7, 113.
26. Gagel, B.; Reinartz, P.; Dimartino, E.; Zimny, M.; Pinkawa, M.; Maneschi, P.; Stanzel, S.; Hamacher, K.; Coenen, H. H.; Westhofen, M.; Bull, U.; Eble, M. J., pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004, 180 (10), 616-22.
27. Bentzen, L.; Keiding, S.; Nordsmark, M.; Falborg, L.; Hansen, S. B.; Keller, J.; Nielsen, O. S.; Overgaard, J., Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003, 67 (3), 339-44.
28. Bentzen, L.; Keiding, S.; Horsman, M. R.; Falborg, L.; Hansen, S. B.; Overgaard, J., Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography-a study evaluating [18F]Fluoro-2-deoxy-D-glucose. Acta Oncol 2000, 39 (5), 629-37.
29. Wyss, M. T.; Honer, M.; Schubiger, P. A.; Ametamey, S. M., NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006, 33 (3), 311-8.
30. Zanzonico, P.; Campa, J.; Polycarpe-Holman, D.; Forster, G.; Finn, R.; Larson, S.; Humm, J.; Ling, C., Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl Med Biol 2006, 33 (1), 65-70.
31. Oswald, J.; Treite, F.; Haase, C.; Kampfrath, T.; Mading, P.; Schwenzer, B.; Bergmann, R.; Pietzsch, J., Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett 2007, 254 (1), 102-10.
32. Dence, C. S.; Ponde, D. E.; Welch, M. J.; Lewis, J. S., Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol 2008, 35 (6), 713-20.
33. Ballinger, J. R., Imaging hypoxia in tumors. Semin Nucl Med 2001, 31 (4), 321-9.
34. Valk, P. E.; Mathis, C. A.; Prados, M. D.; Gilbert, J. C.; Budinger, T. F., Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole. J Nucl Med 1992, 33 (12), 2133-7.
35. Rasey, J. S.; Koh, W. J.; Evans, M. L.; Peterson, L. M.; Lewellen, T. K.; Graham, M. M.; Krohn, K. A., Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36 (2), 417-28.
36. Rajendran, J. G.; Schwartz, D. L.; O'Sullivan, J.; Peterson, L. M.; Ng, P.; Scharnhorst, J.; Grierson, J. R.; Krohn, K. A., Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006, 12 (18), 5435-41.
37. Hicks, R. J.; Rischin, D.; Fisher, R.; Binns, D.; Scott, A. M.; Peters, L. J., Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005, 32 (12), 1384-91.
38. Rischin, D.; Hicks, R. J.; Fisher, R.; Binns, D.; Corry, J.; Porceddu, S.; Peters, L. J., Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006, 24 (13), 2098-104.
39. Nehmeh, S. A.; Lee, N. Y.; Schroder, H.; Squire, O.; Zanzonico, P. B.; Erdi, Y. E.; Greco, C.; Mageras, G.; Pham, H. S.; Larson, S. M.; Ling, C. C.; Humm, J. L., Reproducibility of intratumor distribution of (18)F- fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 70 (1), 235-42.
40. Gronroos, T.; Eskola, O.; Lehtio, K.; Minn, H.; Marjamaki, P.; Bergman, J.; Haaparanta, M.; Forsback, S.; Solin, O., Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 2001, 42 (9), 1397-404.
41. Gronroos, T.; Bentzen, L.; Marjamaki, P.; Murata, R.; Horsman, M. R.; Keiding, S.; Eskola, O.; Haaparanta, M.; Minn, H.; Solin, O., Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004, 31 (4), 513-20.
42. Tolvanen, T.; Lehtio, K.; Kulmala, J.; Oikonen, V.; Eskola, O.; Bergman, J.; Minn, H., 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med 2002, 43 (12), 1674-80.
43. Lehtio, K.; Oikonen, V.; Nyman, S.; Gronroos, T.; Roivainen, A.; Eskola, O.; Minn, H., Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003, 30 (1), 101-8.
44. Lehtio, K.; Eskola, O.; Viljanen, T.; Oikonen, V.; Gronroos, T.; Sillanmaki, L.; Grenman, R.; Minn, H., Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 59 (4), 971-82.
45. Sorger, D.; Patt, M.; Kumar, P.; Wiebe, L. I.; Barthel, H.; Seese, A.; Dannenberg, C.; Tannapfel, A.; Kluge, R.; Sabri, O., [18F] Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003, 30 (3), 317-26.
46. Souvatzoglou, M.; Grosu, A. L.; Roper, B.; Krause, B. J.; Beck, R.; Reischl, G.; Picchio, M.; Machulla, H. J.; Wester, H. J.; Piert, M., Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007, 34 (10), 1566-75.
47. Kumar, P.; Stypinski, D.; Xia, H.; McEwan, A. J. B.; Machulla, H. J.; Wiebe, L. I., Fluoroazomycin arabinoside (FAZA): Synthesis, H-2 and H-3-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. Journal of Labelled Compounds & Radiopharmaceuticals 1999, 42 (1), 3-16.
48. Piert, M.; Machulla, H. J.; Picchio, M.; Reischl, G.; Ziegler, S.; Kumar, P.; Wester, H. J.; Beck, R.; McEwan, A. J.; Wiebe, L. I.; Schwaiger, M., Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005, 46 (1), 106-13.
49. Reischl, G.; Dorow, D. S.; Cullinane, C.; Katsifis, A.; Roselt, P.; Binns, D.; Hicks, R. J., Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA-first small animal PET results. J Pharm Pharm Sci 2007, 10 (2), 203-11.
50. Beck, R.; Roper, B.; Carlsen, J. M.; Huisman, M. C.; Lebschi, J. A.; Andratschke, N.; Picchio, M.; Souvatzoglou, M.; Machulla, H. J.; Piert, M., Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007, 48 (6), 973-80.
51. Busk, M.; Horsman, M. R.; Jakobsen, S.; Keiding, S.; van der Kogel, A. J.; Bussink, J.; Overgaard, J., Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 2008, 70 (4), 1202-12.
52. Grosu, A. L.; Souvatzoglou, M.; Roper, B.; Dobritz, M.; Wiedenmann, N.; Jacob, V.; Wester, H. J.; Reischl, G.; Machulla, H. J.; Schwaiger, M.; Molls, M.; Piert, M., Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69 (2), 541-51.
53. Dearling, J. L.; Lewis, J. S.; Mullen, G. E.; Welch, M. J.; Blower, P. J., Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002, 7 (3), 249-59.
54. Vavere, A. L.; Lewis, J. S., Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007, (43), 4893-902.
55. Young, H.; Carnochan, P.; Zweit, J.; Babich, J.; Cherry, S.; Ott, R., Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med 1994, 21 (4), 336-41.
56. Fujibayashi, Y.; Taniuchi, H.; Yonekura, Y.; Ohtani, H.; Konishi, J.; Yokoyama, A., Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997, 38 (7), 1155-60.
57. Dearling, J. L.; Lewis, J. S.; Mullen, G. E.; Rae, M. T.; Zweit, J.; Blower, P. J., Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998, 25 (7), 788-92.
58. Lewis, J. S.; McCarthy, D. W.; McCarthy, T. J.; Fujibayashi, Y.; Welch, M. J., Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999, 40 (1), 177-83.
59. Lewis, J. S.; Sharp, T. L.; Laforest, R.; Fujibayashi, Y.; Welch, M. J., Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001, 42 (4), 655-61.
60. O'Donoghue, J. A.; Zanzonico, P.; Pugachev, A.; Wen, B.; Smith-Jones, P.; Cai, S.; Burnazi, E.; Finn, R. D.; Burgman, P.; Ruan, S.; Lewis, J. S.; Welch, M. J.; Ling, C. C.; Humm, J. L., Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61 (5), 1493-502.
61. Dehdashti, F.; Mintun, M. A.; Lewis, J. S.; Bradley, J.; Govindan, R.; Laforest, R.; Welch, M. J.; Siegel, B. A., In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30 (6), 844-50.
62. Dehdashti, F.; Grigsby, P. W.; Mintun, M. A.; Lewis, J. S.; Siegel, B. A.; Welch, M. J., Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55 (5), 1233-8.
63. Dehdashti, F.; Grigsby, P. W.; Lewis, J. S.; Laforest, R.; Siegel, B. A.; Welch, M. J., Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49 (2), 201-5.
64. Dietz, D. W.; Dehdashti, F.; Grigsby, P. W.; Malyapa, R. S.; Myerson, R. J.; Picus, J.; Ritter, J.; Lewis, J. S.; Welch, M. J.; Siegel, B. A., Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008, 51 (11), 1641-8.
65. Chao, K. S.; Bosch, W. R.; Mutic, S.; Lewis, J. S.; Dehdashti, F.; Mintun, M. A.; Dempsey, J. F.; Perez, C. A.; Purdy, J. A.; Welch, M. J., A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001, 49 (4), 1171-82.
66. Lewis, J. S.; Laforest, R.; Dehdashti, F.; Grigsby, P. W.; Welch, M. J.; Siegel, B. A., An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008, 49 (7), 1177-82.